Azvudine therapy of common COVID‐19 in hemodialysis patients-Reference-Cited by-同舟云学术

Azvudine therapy of common COVID‐19 in hemodialysis patients

Published:2023-07-31 Issue:8 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Shang Shunlai¹²^ORCID,Fu Bo²,Geng Yanqiu³,Zhang Jian⁴,Zhang Dawei⁵,Xiao Fenglin⁶,Sheng Zhaojun⁷,Zhai Jingbo⁸,Li Wenge¹,Chen Xiangmei²,Zheng Chunfu⁹^ORCID,Li Qinggang²

Affiliation:

1. Department of Nephrology China‐Japan Friendship Hospital Beijing China

2. Department of Nephrology, The First Medical Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Chinese PLA Institute of Nephrology, National Key Laboratory of Kidney Diseases National Clinical Research Center for Kidney Diseases Beijing China

3. Department of Nephrology, The Third Medical Center Chinese PLA General Hospital Beijing China

4. Department of Nephrology, The Fourth Medical Center Chinese PLA General Hospital Beijing China

5. Senior Department of Infectious Diseases of the Fifth Medical Center PLA General Hospital Beijing China

6. Department of Nephrology, The Sixth Medical Center Chinese PLA General Hospital Beijing China

7. College of Pulmonary and Critical Care Medicine the First Medical Center Chinese PLA General Hospital Beijing China

8. Key Laboratory of Zoonose Prevention and Control at Universities of Inner Mongolia Autonomous Region, Medical College Inner Mongolia Minzu University Tongliao China

9. Guangzhou Eighth People's Hospital Guangzhou Medical University Guangzhou City Guangdong Province China

Abstract

AbstractThere is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients. After matching for age, sex, and other factors, 182 patients in the basic treatment group and 182 in the FNC group were included. The negative nucleic acid conversion rate of the FNC group was significantly higher than that of the basic treatment group, and viral loads, interleukin‐6, and C‐reactive protein were significantly lower than those of the basic treatment group (p < 0.05). There were no significant differences in liver function, renal function, or the number of adverse events between the two groups (p > 0.05). In conclusion, our study has provided novel evidence suggesting that the FNC scheme may be safe and effective compared to the basic treatment of hemodialysis patients with common COVID‐19.

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.29007

Reference29 articles.

1. Variation in the ACE2 receptor has limited utility for SARS-CoV-2 host prediction

2. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

3. Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings

4. Characteristics of natural immunity to SARS-CoV-2 over time in wait-listed dialysis patients and recent kidney transplant recipients

5. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial;Journal of Medical Virology;2023-12